Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

This trial is studying whether combining two cancer drugs — lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy) — can work as a maintenance treatment for patients with advanced pancreatic cancer whose disease has not progressed during first or second-line chemotherapy. **You may be eligible if...** - You are 18 or older with a good performance status (able to carry out normal activities) - You have advanced pancreatic cancer that cannot be surgically removed - You have received at least 16 weeks of chemotherapy and your disease is stable or responding - Your last chemotherapy was within the past 30 days - You have not previously received immunotherapy drugs (like anti-PD-1 or anti-PD-L1 agents) - You have adequate blood counts and organ function - You are not pregnant or breastfeeding and agree to use contraception **You may NOT be eligible if...** - You have uncontrolled high blood pressure - You have active autoimmune disease requiring systemic treatment in the past 2 years - You have active brain metastases or a history of certain serious heart conditions - You have a known HIV, active hepatitis B or C infection - You cannot swallow oral medications - You have active serious infections or recent live vaccine Talk to your doctor to see if this trial is right for you.